Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
2 hedge funds and large institutions have $26.5K invested in Therapix Biosciences Ltd. in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% less funds holding
Funds holding: 4 → 2 (-2)
92% less capital invested
Capital invested by funds: $333K → $26.5K (-$306K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$125K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$98K |
| 3 |
Morgan Stanley
New York
|
-$76.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $26K | -$76.6K | -24,711 | -71% |
|
|
APA
2
American Portfolios Advisors
Holbrook,
New York
| $500 | – | – | – |
|
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$125K | -40,055 | Closed |
|
|
CH
4
CVI Holdings
Wilmington,
Delaware
| – | -$98K | -31,397 | Closed |
|
TRPX Hedge Fund Activity: Q2 2019 in Review
2 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q2 2019, worth a combined $26.5K — down 92% from $333K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of TRPX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $125K sold.
- 2 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q2 2019, down from 4 in Q1 2019.
- Funds reported $26.5K of Therapix Biosciences Ltd. stock for Q2 2019, down 92% quarter-over-quarter.
- 0 funds opened new Therapix Biosciences Ltd. positions in Q2 2019 and 2 closed out, a net change of -2 holders.
- The largest Therapix Biosciences Ltd. seller in Q2 2019 was Hudson Bay Capital Management, an estimated $125K sold.
Based on aggregated 13F filings for Q2 2019.